Latest Period
Q1 2026
Security Snapshot
Nasus Pharma Ltd - Common Stock, par value $0.01 per share (NSRX) Institutional Ownership
CUSIP: M7071P109
13F Institutional Holders and Ownership History from Q3 2025 to Q1 2026
Institutions Reporting
9
Shares (Excl. Options)
2,174,274
Price
$2.22
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Common Stock, par value $0.01 per share
- Symbol
- NSRX on NYSE
- All holders as of 31 Mar 2026
- Q1 2026
- Total 13F shares
- 2,174,274
- Total 13F value
- $4,826,539
- Portfolio coverage rank
- 0%
- Share change
- +2,171,896
- Value change
- +$4,821,260
- Number of holders
- 9
- Shares outstanding
- 11,710,811
- SEC-reported price per share
- $3.17
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
2 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Key facts
- NSRX - Nasus Pharma Ltd - Common Stock, par value $0.01 per share is tracked under CUSIP M7071P109.
- 9 institutions reported positions in Q1 2026.
- 6 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 2 to 9 between Q4 2025 and Q1 2026.
- SEC-reported value moved from $21,759 to $4,826,539.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 9 institutions filings for Q1 2026.
Security key
M7071P109
Latest holder period
Q1 2026
13F holders
9
13D/G owners
6
CIK / CUSIP context first
Open Q1 2026 holders
NSRX full holder history
Nasus Pharma Ltd SEC filings
Nasus Pharma Ltd company facts
Nasus Pharma Ltd insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP M7071P109:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
6
Security
NSRX
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| Gilboa Udi | 21% | $14,354,898 | 1,901,311 | Udi Gilboa | 30 Sep 2025 | |||
| Megiddo Dalia | 21% | $14,260,991 | 1,888,873 | Dr. Dalia Megiddo | 30 Sep 2025 | |||
| Hershman Ronnie | 15% | $10,445,516 | 1,383,512 | Dr. Ronnie Hershman | 30 Sep 2025 | |||
| BALYASNY ASSET MANAGEMENT L.P. | 10% | $2,714,191 | 1,169,910 | Balyasny Asset Management L.P. | 31 Mar 2026 | |||
| Funicular Funds, LP | 5.2% | $3,309,730 | 612,913 | Funicular Funds, LP | 31 Mar 2026 | |||
| Capital Point Ltd. | 6.4% | 575,129 | Capital Point Ltd. | 14 Aug 2025 |
As of 31 Mar 2026, 9 institutional investors reported holding 2,174,274 shares of Nasus Pharma Ltd - Common Stock, par value $0.01 per share (NSRX). This represents 19% of the company’s total 11,710,811 outstanding shares.
13F concentration
Top 9 institutional shareholders
Largest 13F positions for this security by reported shares and value.
Top holder share
19%
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| Balyasny Asset Management L.P. | 7.7% | 898,473 | 0% | $1,994,610 | |
| Cable Car Capital, LP | 5.1% | 601,998 | 0.46% | $1,336,436 | |
| Velan Capital Investment Management LP | 3.1% | 359,390 | 0.5% | $797,846 | |
| Hudson Bay Capital Management LP | 1.2% | 134,771 | 0% | $299,192 | |
| Bleichroeder LP | 0.77% | 89,848 | 0.03% | $199,463 | |
| Empery Asset Management, LP | 0.39% | 45,803 | 0.12% | $101,683 | |
| HRT FINANCIAL LP | 0.33% | 38,897 | 0% | $86,000 | |
| UBS Group AG | 0.03% | 3,094 | +719% | 0% | $6,869 |
| MORGAN STANLEY | 0.02% | 2,000 | 0% | 0% | $4,440 |
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
3
Latest
Q1 2026
Rows shown
1-3 of 3